Stock listing

TSX:BCT BriaCell Therapeutics Corp Stock

Home listing (TSX) of BriaCell Therapeutics Corp

Follow BriaCell Therapeutics Corp into a list and get an email when it puts out news.

Share price · TSX:BCT

$4.40 CAD -0.25 (-5.5%)

Close on Nov 20, 2026

Past year -57.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.34 – $4.45 CADNov 20, 2026
Volume
1,305 sharesNov 20, 2026
Market cap
$38.42M CADAt the close on Nov 20, 2026 · price × 8.73M shares outstanding
52-week range
$3.68 – $18.00 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$37,627 CADMedian day 4,349 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BriaCell Therapeutics Corp logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSX:BCT · Home$4.40 CAD-0.255 (-5.5%)1,305$4.45$4.45$4.34$4.655Close on Nov 20, 2026
NASDAQ:BCTX$3.06 USD-0.10 (-3.2%)109,662$3.14$3.20$3.02$3.16Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:BCT · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.40-0.255-5.5%$4.45$4.45$4.341,305
$4.655-0.295-6.0%$5.00$5.00$4.6555,575
$4.95+0.22+4.7%$4.81$5.07$4.801,118
$4.73-0.16-3.3%$4.74$4.74$4.73600
$4.89-0.01-0.2%$4.86$4.89$4.761,848
$4.90-0.18-3.5%$5.17$5.17$4.901,120
$5.08-0.12-2.3%$5.24$5.24$5.08201
$5.200.000.0%$5.30$5.32$5.181,223
$5.20-0.37-6.6%$5.44$5.53$5.185,132
$5.57+0.96+20.8%$4.60$5.79$4.6021,391
$4.61+0.16+3.6%$4.78$4.85$4.382,901
$4.45+0.25+6.0%$4.28$4.62$4.284,282
$4.20-0.09-2.1%$4.38$4.38$4.208,019
$4.29-0.01-0.2%$4.35$4.52$4.296,326
$4.30-0.35-7.5%$4.60$4.61$4.1511,319
$4.65-0.21-4.3%$5.02$5.02$4.647,126
$4.86-0.15-3.0%$5.01$5.01$4.862,012
$5.01+0.14+2.9%$4.99$5.10$4.774,150
$4.87+0.08+1.7%$5.02$5.03$4.864,182
$4.79-0.05-1.0%$4.78$4.79$4.721,187
$4.84-0.24-4.7%$5.11$5.11$4.774,398
$5.08+0.22+4.5%$4.86$5.08$4.861,504
$4.86+0.05+1.0%$4.78$5.05$4.774,000
$4.81-0.07-1.4%$4.86$4.87$4.811,926
$4.88-0.48-9.0%$5.41$5.41$4.8015,500
$5.36+0.11+2.1%$5.26$5.36$5.26900
$5.25-0.06-1.1%$5.38$5.50$5.253,000
$5.31-0.30-5.3%$5.56$5.56$5.304,300
$5.61+0.05+0.9%$5.56$5.66$5.561,100
$5.56-0.13-2.3%$5.57$5.62$5.554,000
$5.69-0.01-0.2%$5.70$5.73$5.631,700
$5.70-0.23-3.9%$5.92$5.92$5.673,600
$5.93+0.18+3.1%$5.80$6.01$5.763,700
$5.75-0.13-2.2%$6.02$6.11$5.714,700
$5.88-0.22-3.6%$6.09$6.09$5.874,800
$6.10+0.30+5.2%$5.69$6.15$5.6911,800
$5.80+0.07+1.2%$5.68$5.80$5.675,100
$5.73-0.31-5.1%$5.93$6.23$5.7012,700
$6.04+0.02+0.3%$6.14$6.16$5.9610,200
$6.02+0.36+6.4%$5.65$6.20$5.6512,000
$5.66-0.08-1.4%$5.69$5.82$5.663,000
$5.74-0.06-1.0%$5.82$6.11$5.5610,000
$5.80-0.11-1.9%$5.73$5.925$5.645,500
$5.91-0.01-0.2%$5.86$6.11$5.7315,600
$5.92+0.94+18.9%$4.92$6.03$4.9253,200
$4.98+0.06+1.2%$4.95$5.02$4.902,300
$4.92-0.06-1.2%$4.88$4.94$4.856,200
$4.98-0.06-1.2%$5.04$5.06$4.9613,200
$5.04+0.05+1.0%$5.06$5.17$5.033,000
$4.99-0.06-1.2%$4.95$5.03$4.942,000
$5.05+0.20+4.1%$4.99$5.13$4.9015,500
$4.85-0.08-1.6%$4.72$4.95$4.722,300
$4.93+0.06+1.2%$4.84$4.93$4.813,100
$4.87-0.08-1.6%$4.82$4.87$4.82200
$4.95-0.10-2.0%$5.01$5.05$4.936,800
$5.05+0.08+1.6%$4.94$5.06$4.915,600
$4.97-0.22-4.2%$5.17$5.25$4.8313,600
$5.19+0.03+0.6%$5.08$5.20$5.071,100
$5.16-0.46-8.2%$5.45$5.45$5.0618,400
$5.62+0.48+9.3%$5.14$5.62$5.149,900
$5.14+0.32+6.6%$4.94$5.57$4.9418,600
$4.82-0.74-13.3%$5.55$5.55$4.7825,400
$5.56+0.08+1.5%$5.61$5.73$5.509,300
$5.48+0.03+0.6%$5.43$5.75$5.437,400

Splits

3 splits since 2014 · TSX:BCT · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-15Consolidation
1-for-3.2573Consolidation
Ticker
TSX:BCT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TSX
Currency
CAD

What changed lately

Latest news

All BriaCell Therapeutics Corp news

BriaCell Therapeutics Corp on 6ix

Sector
Health care
Industry
Biotechnology
News releases
45 in the last 12 months · 136 in all · newest Nov 6, 2026 · oldest 2007
Decks
13 decks · latest Nov 18, 2026

Where BriaCell Therapeutics Corp is listed

ListingExchangeCountryCurrency
TSX:BCT · Home listing · This pageTSXCanadaCAD
NASDAQ:BCTXNASDAQUnited StatesUSD
Cboe Canada:BCTCboe CanadaCanadaCAD
BOATS:BCTXBOATSUnited StatesUSD
gettex:8BTgettexGermanyEUR
Tradegate:8BTTradegateGermanyEUR
Frankfurt:8BTFrankfurtGermanyEUR
Munich:8BTMunichGermanyEUR

Valuation

Price/book 1.7× against a median of 2.3×: 5th lowest of 11 Biotechnology companies shown. Statements: Year to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
$8.97M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P/TSX Composite
1.07

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BriaCell Therapeutics Corp · TSX:BCTUS$26.79MUS$6.25Mn/an/an/a1.7×n/a0.0×1.07
Holy Stone Healthcare Co., Ltd. · TPEX:4194US$27.49MUS$25.08Mn/an/an/a7.3×n/a0.0×n/a
SoftOx Solutions AS · OSL:SOFTXUS$27.28MUS$25.25Mn/an/an/a11.6×n/a0.0×n/a
Edesa Biotech, Inc. · NASDAQ:EDSAUS$27.02MUS$16.72Mn/an/an/a3.1×n/a0.0×0.47
Amplia Therapeutics Ltd. · ASX:ATXUS$26.86MUS$8.64Mn/an/an/a1.0×n/a0.0×n/a
Nasus Pharma Ltd. · AMEX:NSRXUS$26.82MUS$15.11Mn/an/an/a2.4×n/a0.0×0.99
Telomir Pharmaceuticals, Inc. · NASDAQ:TELOUS$26.82MUS$22.30Mn/an/an/a6.1×n/a0.0×1.74
Alterity Therapeutics Ltd. · ASX:ATHUS$26.78MUS$2.18Mn/an/an/a0.9×n/a0.0×n/a
EyePoint, Inc. · NASDAQ:EYPTUS$26.65M−US$72.44Mn/a−28.1×n/a0.3×n/a0.2×1.36
Aprogen, Inc · KRX:007460US$26.64MUS$21.32Mn/a0.2×n/a0.6×−60.1%0.6×n/a
PolTREG Spolka Akcyjna · GPW:PTGUS$26.08MUS$22.34Mn/a378×n/a2.2×n/a0.1×n/a
Median of the othersUS$26.82MUS$19.02M0.2×2.3×−60.1%0.0×1.18

Forecasts

Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
20.00 CAD · Analysts' mean
EPS, year to Jul 2026
-11.45 · 1 analyst

Team and board

Officers

OfficerRole
William V. WilliamsPresident & Chief Executive Officer
Gadi LevinChief Financial Officer & Corporate Secretary
Giuseppe Del PrioreChief Medical Officer
Jane A. GrossDirector of the Board
Martin E. SchmiegDirector of the Board
Massimo CristofanilliChief, Breast Medical Oncology; Associate Director, Precision Medicine Oncology; Scientific Director, Englander Institute of Precision Medicine
Miguel A. Lopez-LagoChief Scientific Officer
Rebecca TaubDirector of the Board
Vaughn C. Embro-PantalonyDirector of the Board

Board

DirectorRole
Jamieson BondarenkoChairman of the Board
Adam M. BrufskyCo-Director, Comprehensive Breast Cancer Center; Medical Director, Women’s Cancer Center
Massimo CristofanilliChief, Breast Medical Oncology; Associate Director, Precision Medicine Oncology; Scientific Director, Englander Institute of Precision Medicine
William V. WilliamsPresident & Chief Executive Officer

Events

QuarterResultsShare move
Q4 2025Oct 15, 2025 · After close+4.2%
Q3 2025Jun 16, 2025 · After close−0.5%
Q2 2025Mar 12, 2025 · After close−1.4%
Q1 2025Dec 16, 2024 · After close+2.3%
Q4 2024Oct 23, 2024 · After close−2.4%
Q3 2024Jun 14, 2024 · After close+4.2%
Q2 2024Mar 18, 2024 · After close−6.7%
Q1 2024Dec 14, 2023 · After close−1.6%
Q4 2023Oct 25, 2023 · After close−10.7%
Q3 2023Jun 14, 2023 · After close+3.3%
All 15 quarters
QuarterResultsShare move
Q2 2023Mar 15, 2023 · After close+1.0%
Q1 2023Dec 14, 2022 · After close−2.4%
Q4 2022Oct 27, 2022 · After close+2.3%
Q3 2022Jun 13, 2022 · After close−0.8%
Q2 2022Mar 14, 2022 · After close−0.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck27 slidesNov 18, 2026
Investor Presentation (September 2026)Investor deck27 slidesSep 28, 2026
Technical Presentation (June 2024)Technical21 slidesJun 3, 2024
Investor Presentation (April 2021)Investor deck17 slidesApril 2021
Investor Presentation (February 2021)Investor deck15 slidesFebruary 2021
3rd Annual Biologics World Nordic 2020 ConferenceConference31 slidesSep 30, 2020
Investor Presentation (July 2019)Investor deck41 slidesJuly 2019
Investor Presentation (October 2018)Investor deck42 slidesOctober 2018
Investor Presentation (October 2018)Investor deck43 slidesOctober 2018
Investor Presentation (September 2018)Investor deck38 slidesSeptember 2018
All 13 decks
DeckKindSlidesDate
Investor Presentation (July 2018)Investor deck39 slidesJuly 2018
Investor Presentation (May 2018)Investor deck37 slidesMay 2018
Investor Presentation (July 2016)Investor deck24 slidesJuly 2016

Open Decks

Financings

RaiseDate
Public offering of units (one common share or pre-funded warrant and one warrant)
Closed: US$30M raised · US$5.59 a unit · 1 warrant at US$6.93 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Working capital, general corporate purposes and advancing the company's business objectives
Jan 15, 2026
Public offering of units (one common share or pre-funded warrant and one warrant)
Closed: US$15M raised · US$1.25 a unit · 1 warrant at US$1.5 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Working capital, general corporate purposes and advancing business objectives
Jul 16, 2025
Public offering of units (one common share or pre-funded warrant and one warrant)
Closed: US$13.8M raised · US$4.5 a unit · 1 warrant at US$5.25 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Working capital, general corporate purposes and advancement of business objectives
Apr 28, 2025

Open Financings · Read by 6ix AI from the company's releases

Drill core

ReleaseDateProjectHeadline hole
Ansell Capital Corp announces additional drill results at Charlotte Property, Yukon
DDH-11-255 1.03 g/t Au over 2.90 m from 108.10 m
DDH-11-256 0.41 g/t Au over 4.60 m from 23.30 m
Nov 8, 2011Charlotte propertyDDH-11-254 3.38 g/t Au over 12.40 m from 92.40 m
ANSELL CAPITAL CORP. SUMMARIZES DRILL RESULTS FROM THE CHARLOTTE PROPERTY NEAR CARMACKS, YUKON TERRITORY
DDH-10-241 1.77 g/t Au over 24.25 m from 58.25 m
DDH-10-242 8.61 g/t Au over 5.65 m from 15.85 m
Nov 8, 2010Charlotte propertyDDH-10-240 1.66 g/t Au over 31.25 m from 59.60 m

Open Drill core

Properties

PropertyPlaceOn 6ixLast news
Charlotte propertyYukon, Canada2 drill releasesNov 8, 2011

Open Properties

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2022FY2021FY2021
Research and development29.2M21.3M27.2M15.3M8.02M2.02M
Operating income-36.1M-27.2M-33.3M-23.3M-15.3M-6.98M
Depreciation and amortization104.1K91.4K68.6K15.3K15.3K
EBITDA-36.0M-27.1M-33.3M-15.3M-6.96M
Interest expense29.6K37.0K97978.6K
Income before tax35.3M26.6M4.93M20.3M-26.8M-13.8M
Income tax00
Net income-34.9M-26.3M-4.79M-20.3M-26.8M-13.8M
Earnings per share, basic-6.97-62.19-43.68-1.30-1.73-3.06
Earnings per share, diluted-6.97-62.19-43.68-1.30-1.73

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2022FY2021FY2021
Cash and equivalents9.85M10.5M862.1K21.3M41.0M57.3M
Short-term investments10.7M7.37M
Receivables18.9K24.1K12.6K
Current assets22.0M19.9M3.65M26.9M42.3M57.8M
Property, plant and equipment319.8K296.8K388.2K2.50K2.50K
Total assets23.6M21.6M5.87M27.2M42.6M58.0M
Current liabilities7.98M3.98M7.46M1.80M941.1K556.8K
Shareholders' equity15.6M17.3M-2.68M-3.78M10.3M27.7M
Shares outstanding8.71M1.88M121.9K16.0M15.5M15.5M15.3M15.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations-28.7M-28.2M-24.1M-23.7M-12.5M-7.75M
Capital spending-127.0K-456.8K
Free cash flow-28.8M-24.6M
Cash from investing-3.81M-7.65M-681.8K
Cash from financing31.8M45.4M4.42M3.95M-3.74M65.0M
Change in cash-641.4K9.63M-20.4M-19.8M-16.2M57.2M

Open Financials

Filings

FilingDateTypeFiled with
10-K · Annual reportOct 28, 2026Annual reportSEC
8-K · Current reportJun 26, 2026Current reportSEC
10-Q · Quarterly reportJun 9, 2026Quarterly reportSEC
8-K · Current reportJun 2, 2026Material contractSEC
424B5 · ProspectusJun 2, 2026Offer documentSEC
8-K · Current reportMar 31, 2026Current reportSEC
10-Q · Quarterly reportMar 10, 2026Quarterly reportSEC
8-K · Current reportMar 9, 2026Meeting outcomeSEC
25-NSEFeb 26, 2026Other filingsSEC
8-K · Current reportFeb 20, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
DEF 14A · Proxy statementFeb 12, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJan 23, 2026Big-stake noticeSEC
8-K · Current reportJan 15, 2026Material contractSEC
424B4 · ProspectusJan 14, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 14, 2026Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJan 13, 2026Offer documentSEC
CERT · Exchange's certificate of listingJan 13, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJan 13, 2026Other filingsSEC
CORRESP · Letter to the SECJan 8, 2026Other filingsSEC
CORRESP · Letter to the SECJan 8, 2026Other filingsSEC
CORRESP · Letter to the SECJan 6, 2026Other filingsSEC
CORRESP · Letter to the SECJan 6, 2026Other filingsSEC
8-K · Current reportDec 29, 2025Current reportSEC
FWP · Free writing prospectusDec 23, 2025Offer documentSEC
S-1 · Registration statementDec 23, 2025Offer documentSEC
10-Q · Quarterly reportDec 11, 2025Quarterly reportSEC
8-K · Current reportNov 28, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
DRSLTR · Letter to the SEC with a draftOct 16, 2025Other filingsSEC
DRS · Draft registration statementOct 16, 2025Offer documentSEC
10-K · Annual reportOct 15, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeOct 10, 2025Big-stake noticeSEC
8-K · Current reportAug 25, 2025Current reportSEC
S-8 · Registration statement for employee plansJul 31, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 22, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 21, 2025Big-stake noticeSEC
8-K · Current reportJul 16, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveJul 16, 2025Other filingsSEC
424B4 · ProspectusJul 15, 2025Offer documentSEC
CORRESP · Letter to the SECJul 15, 2025Other filingsSEC
CORRESP · Letter to the SECJul 15, 2025Other filingsSEC
CORRESP · Letter to the SECJul 14, 2025Other filingsSEC
CORRESP · Letter to the SECJul 14, 2025Other filingsSEC
CORRESP · Letter to the SECJul 11, 2025Other filingsSEC
CORRESP · Letter to the SECJul 11, 2025Other filingsSEC
FWP · Free writing prospectusJul 10, 2025Offer documentSEC
S-1/A · Registration statement, amendedJul 10, 2025Offer documentSEC
S-1/A · Registration statement, amendedJul 9, 2025Offer documentSEC
FWP · Free writing prospectusJul 8, 2025Offer documentSEC
CORRESP · Letter to the SECJul 8, 2025Other filingsSEC
CORRESP · Letter to the SECJul 8, 2025Other filingsSEC
S-1 · Registration statementJul 8, 2025Offer documentSEC
UPLOAD · Letter from the SECJun 24, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftJun 18, 2025Other filingsSEC
DRS · Draft registration statementJun 18, 2025Offer documentSEC
8-K · Current reportJun 18, 2025Current reportSEC
10-Q · Quarterly reportJun 16, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2025Big-stake noticeSEC
8-K · Current reportApr 28, 2025Material contractSEC
424B4 · ProspectusApr 28, 2025Offer documentSEC
424B4 · ProspectusApr 28, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 25, 2025Other filingsSEC
S-1MEF · Registration of more shares for the same offeringApr 24, 2025Offer documentSEC
CERT · Exchange's certificate of listingApr 24, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeApr 24, 2025Other filingsSEC
S-1/A · Registration statement, amendedApr 23, 2025Offer documentSEC
FWP · Free writing prospectusApr 22, 2025Offer documentSEC
CORRESP · Letter to the SECApr 22, 2025Other filingsSEC
CORRESP · Letter to the SECApr 22, 2025Other filingsSEC
CORRESP · Letter to the SECApr 22, 2025Other filingsSEC
S-1 · Registration statementApr 22, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 24, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftMar 12, 2025Other filingsSEC
DRS · Draft registration statementMar 12, 2025Offer documentSEC
10-Q · Quarterly reportMar 12, 2025Quarterly reportSEC
8-K · Current reportMar 12, 2025Current reportSEC
8-K · Current reportFeb 13, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
8-K · Current reportFeb 6, 2025Meeting outcomeSEC
8-K · Current reportFeb 5, 2025Material contractSEC
424B5 · ProspectusFeb 4, 2025Offer documentSEC
424B5 · ProspectusFeb 3, 2025Offer documentSEC
8-K · Current reportJan 28, 2025Current reportSEC
8-K · Current reportJan 3, 2025Current reportSEC
8-K · Current reportJan 3, 2025Current reportSEC
DEFA14A · Additional proxy materialJan 3, 2025Meeting noticeSEC
DEF 14A · Proxy statementDec 17, 2024Meeting noticeSEC
10-Q · Quarterly reportDec 16, 2024Quarterly reportSEC
8-K · Current reportDec 16, 2024Current reportSEC
8-K · Current reportDec 13, 2024Material contractSEC
424B5 · ProspectusDec 12, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedDec 12, 2024Big-stake noticeSEC
424B5 · ProspectusDec 11, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedDec 10, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedDec 5, 2024Big-stake noticeSEC
8-K · Current reportNov 25, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 1, 2024Current reportSEC
10-K · Annual reportOct 28, 2024Annual reportSEC
8-K · Current reportOct 2, 2024Material contractSEC
424B5 · ProspectusOct 2, 2024Offer documentSEC
8-K · Current reportOct 1, 2024Current reportSEC
SC 13G · Big-stake noticeSep 16, 2024Big-stake noticeSEC
8-K · Current reportSep 12, 2024Material contractSEC
424B5 · ProspectusSep 11, 2024Offer documentSEC
8-K · Current reportSep 11, 2024Current reportSEC
8-K · Current reportAug 23, 2024Current reportSEC
8-K · Current reportJul 18, 2024Current reportSEC
8-K · Current reportJul 5, 2024Current reportSEC
10-Q · Quarterly reportJun 14, 2024Quarterly reportSEC
8-K · Current reportJun 14, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMay 24, 2024Big-stake noticeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 17, 2024Material contractSEC
424B5 · ProspectusMay 16, 2024Offer documentSEC
8-K · Current reportApr 2, 2024Current reportSEC
10-Q · Quarterly reportMar 18, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveFeb 1, 2024Other filingsSEC
8-K · Current reportJan 31, 2024Meeting outcomeSEC
CORRESP · Letter to the SECJan 29, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 29, 2024Other filingsSEC
S-3 · Registration statementJan 22, 2024Offer documentSEC
DEF 14A · Proxy statementJan 9, 2024Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2024Big-stake noticeSEC
8-K · Current reportDec 20, 2023Current reportSEC
10-Q · Quarterly reportDec 14, 2023Quarterly reportSEC
8-K · Current reportDec 14, 2023Current reportSEC
8-K · Current reportNov 30, 2023Current reportSEC
8-K · Current reportNov 3, 2023Current reportSEC
10-K · Annual reportOct 25, 2023Annual reportSEC
8-K · Current reportOct 25, 2023Current reportSEC
8-K · Current reportSep 8, 2023Current reportSEC
8-K · Current reportSep 7, 2023Current reportSEC
8-K · Current reportAug 31, 2023Current reportSEC
8-K · Current reportAug 31, 2023Current reportSEC
8-K · Current reportAug 25, 2023Current reportSEC
8-K · Current reportAug 21, 2023Meeting outcomeSEC
DEF 14A · Proxy statementJul 26, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 30, 2023Meeting noticeSEC
8-K · Current reportJun 27, 2023Current reportSEC
10-Q · Quarterly reportJun 14, 2023Quarterly reportSEC
8-K · Current reportMay 31, 2023Material contractSEC
8-K · Current reportMay 22, 2023FinancingSEC
8-K · Current reportMay 15, 2023Material contractSEC
8-K · Current reportApr 17, 2023Current reportSEC
8-K · Current reportMar 30, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveMar 29, 2023Other filingsSEC
POS AM · Amendment to an effective registrationMar 20, 2023Offer documentSEC
UPLOAD · Letter from the SECMar 16, 2023Other filingsSEC
10-Q · Quarterly reportMar 15, 2023Quarterly reportSEC
CORRESP · Letter to the SECMar 13, 2023Other filingsSEC
UPLOAD · Letter from the SECMar 8, 2023Other filingsSEC
8-K · Current reportFeb 23, 2023Current reportSEC
8-K · Current reportFeb 15, 2023Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
8-K · Current reportFeb 10, 2023Current reportSEC
8-K · Current reportJan 24, 2023Current reportSEC
8-K · Current reportJan 23, 2023Current reportSEC
8-K · Current reportJan 18, 2023Current reportSEC
DEF 14A · Proxy statementJan 17, 2023Meeting noticeSEC
8-K · Current reportJan 10, 2023Current reportSEC
PRE 14A · Preliminary proxy statementJan 5, 2023Meeting noticeSEC
4 · Change in ownershipDec 28, 2022Insider tradeSEC
4 · Change in ownershipDec 28, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
10-Q · Quarterly reportDec 14, 2022Quarterly reportSEC
8-K · Current reportDec 8, 2022Current reportSEC
8-K · Current reportNov 30, 2022Current reportSEC
8-K · Current reportNov 10, 2022Current reportSEC
10-K · Annual reportOct 27, 2022Annual reportSEC
8-K · Current reportOct 27, 2022ResultsSEC
8-K · Current reportOct 21, 2022Current reportSEC
8-K · Current reportSep 14, 2022Current reportSEC
3 · Initial statement of ownershipAug 11, 2022Insider tradeSEC
8-K · Current reportAug 4, 2022Material contractSEC
3 · Initial statement of ownershipAug 2, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2022Insider tradeSEC
SC 13G · Big-stake noticeAug 1, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerJul 18, 2022Current reportSEC
6-K · Report of a foreign issuerJul 5, 2022Current reportSEC
6-K · Report of a foreign issuerJun 29, 2022Current reportSEC
6-K · Report of a foreign issuerJun 24, 2022Current reportSEC
6-K · Report of a foreign issuerJun 13, 2022Current reportSEC
6-K · Report of a foreign issuerMay 18, 2022Current reportSEC
SC 13G · Big-stake noticeApr 25, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerApr 13, 2022Current reportSEC
6-K · Report of a foreign issuerApr 12, 2022Current reportSEC
6-K · Report of a foreign issuerApr 7, 2022Current reportSEC
424B3 · ProspectusMar 21, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 17, 2022Other filingsSEC
6-K · Report of a foreign issuerMar 15, 2022Current reportSEC

This page holds 200 of 324 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BriaCell Therapeutics Corp’s releases · as of Jan 15, 2026

Common shares
8,732,381
Fully diluted
29,565,772

Fully diluted

LineSharesAs of
Common shares8,732,381
Warrants20,833,391Jan 15, 2026

Warrants and options

Lot
Warrants · US$6.93 · expire about Jan 2031
Warrants · US$1.50 · expire about Jul 2030
Warrants · US$5.25 · expire about Apr 2030

Share count over time

CountShares
Nov 22, 20268,732,381

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Cable Car Capital, LP217K2.5%US$928KNo changeNov 16, 2026
Iridian Asset Management LLC65,0000.74%US$278KNo changeOct 23, 2026
Hrt Financial LP35,2480.40%US$150K+344Nov 13, 2026
Jane Street21,7340.25%US$93,022−4,781Nov 12, 2026
Citadel10,4320.12%US$44,649NewNov 16, 2026
National Bank Of Canada2,1720.02%US$8,852+369Nov 13, 2026
Federation des caisses Desjardins du Quebec450<0.01%US$1,839No changeNov 16, 2026
Morgan Stanley420<0.01%US$1,798−613Nov 13, 2026
UBS373<0.01%US$1,596−43,269Nov 10, 2026
Allworth Financial LP100<0.01%US$428No changeNov 17, 2026
All 18 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Ssa Swiss Advisors AG37<0.01%US$159No changeNov 10, 2026
Provenance Wealth Advisors, LLC34<0.01%US$146NewOct 30, 2026
TD19<0.01%US$78No changeOct 16, 2026
Group One Trading LLC16<0.01%US$68No changeNov 10, 2026
Caitong International Asset Management Co., Ltd10<0.01%US$43−24Oct 29, 2026
HHM Wealth Advisors, LLC6<0.01%US$26No changeNov 10, 2026
Robinhood Markets, Inc.1<0.01%US$4First reportNov 18, 2026
Wells Fargo1<0.01%US$4No changeNov 16, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Nasdaq Composite Index Fund3,2310.04%US$11,761NewMay 31, 2026

Big stakes

HolderStakeSharesDate
Citadel Advisors LLC9.99%717KJan 15, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gadi Levin
Other companies: Clearmind Medicine Inc. (VP Finance · Since at least Nov 4, 2026); Sativus Tech Corp. (CEO · Dec 15, 2021 – Dec 15, 2021 · Past); Quantum X Labs Inc. (Chief Financial Officer · Apr 18, 2017 – Apr 18, 2017 · Past)
Chief Financial Officer & Corporate Secretary · Since at least Aug 1, 2022
Jane A. Gross
Other companies: aTyr Pharma, Inc. (Director · Since at least Jun 28, 2019); Aptevo Therapeutics Inc. (SVP & Chief Scientific Officer · Sep 1, 2016 – Jan 29, 2021 · Past)
Director of the Board · Since at least Aug 1, 2022
Rebecca Taub
Other companies: Madrigal Pharmaceuticals, Inc. (Founder and Director · Since at least Jul 22, 2016); Via Pharmaceuticals Inc (SVP, Research & Development · Jan 14, 2008 – Dec 5, 2008 · Past)
Director of the Board · Since at least Aug 1, 2022
Giuseppe Del Priore
Other companies: Tyme Technologies Inc (Chief Medical Officer · Jul 27, 2017 – May 7, 2020 · Past)
Chief Medical Officer · Since at least Aug 1, 2022
Adam M. BrufskyCo-Director, Comprehensive Breast Cancer Center; Medical Director, Women’s Cancer Center · Since at least Jun 1, 2026
Jamieson BondarenkoChairman of the Board · Since at least Aug 1, 2022
Marc LustigDirector · Aug 1, 2022 – May 14, 2024 · Past
Martin E. SchmiegDirector of the Board · Since at least Aug 1, 2022
Massimo CristofanilliChief, Breast Medical Oncology; Associate Director, Precision Medicine Oncology; Scientific Director, Englander Institute of Precision Medicine · Since at least Nov 4, 2026
Miguel A. Lopez-LagoChief Scientific Officer · Since at least Aug 1, 2022
All 12 people
PersonSeat
Vaughn C. Embro-PantalonyDirector of the Board · Since at least Aug 1, 2022
William V. WilliamsPresident & Chief Executive Officer · Since at least Aug 1, 2022

Open People

Log in to ask 6ix AI your own questions about BriaCell Therapeutics Corp.